FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2012702392> ?p ?o ?g. }

• W2012702392 abstract "The sodium-dependent glucose co-transporter-2 (SGLT2) is expressed in absorptive epithelia of the renal tubules. Remogliflozin etabonate (RE) is the prodrug of remogliflozin, the active entity that inhibits SGLT2. An inhibitor of this pathway would enhance urinary glucose excretion (UGE), and potentially improve plasma glucose concentrations in diabetic patients. RE is intended for use for the treatment of type 2 diabetes mellitus (T2DM) as monotherapy and in combination with existing therapies. Metformin, a dimethylbiguanide, is an effective oral antihyperglycemic agent widely used for the treatment of T2DM.This was a randomized, open-label, repeat-dose, two-sequence, cross-over study in 13 subjects with T2DM. Subjects were randomized to one of two treatment sequences in which they received either metformin alone, RE alone, or both over three, 3-day treatment periods separated by two non-treatment intervals of variable duration. On the evening before each treatment period, subjects were admitted and confined to the clinical site for the duration of the 3-day treatment period. Pharmacokinetic, pharmacodynamic (urine glucose and fasting plasma glucose), and safety (adverse events, vital signs, ECG, clinical laboratory parameters including lactic acid) assessments were performed at check-in and throughout the treatment periods. Pharmacokinetic sampling occurred on Day 3 of each treatment period.This study demonstrated the lack of effect of RE on steady state metformin pharmacokinetics. Metformin did not affect the AUC of RE, remogliflozin, or its active metabolite, GSK279782, although Cmax values were slightly lower for remogliflozin and its metabolite after co-administration with metformin compared with administration of RE alone. Metformin did not alter the pharmacodynamic effects (UGE) of RE. Concomitant administration of metformin and RE was well tolerated with minimal hypoglycemia, no serious adverse events, and no increase in lactic acid.Coadministration of metformin and RE was well tolerated in this study. The results support continued development of RE as a treatment for T2DM.ClinicalTrials.gov, NCT00376038." @default.
• W2012702392 created "2016-06-24" @default.
• W2012702392 creator A5003799255 @default.
• W2012702392 creator A5004226439 @default.
• W2012702392 creator A5015238083 @default.
• W2012702392 creator A5041396494 @default.
• W2012702392 creator A5048256222 @default.
• W2012702392 creator A5050132762 @default.
• W2012702392 creator A5080178643 @default.
• W2012702392 creator A5090786280 @default.
• W2012702392 date "2013-04-30" @default.
• W2012702392 modified "2023-10-18" @default.
• W2012702392 title "Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus" @default.
• W2012702392 cites W104021497 @default.
• W2012702392 cites W1831814133 @default.
• W2012702392 cites W1970063460 @default.
• W2012702392 cites W2000047428 @default.
• W2012702392 cites W2002760082 @default.
• W2012702392 cites W2019017315 @default.
• W2012702392 cites W2020474316 @default.
• W2012702392 cites W2036839655 @default.
• W2012702392 cites W2037698344 @default.
• W2012702392 cites W2041780259 @default.
• W2012702392 cites W2053119517 @default.
• W2012702392 cites W2056391616 @default.
• W2012702392 cites W2078089300 @default.
• W2012702392 cites W2081532336 @default.
• W2012702392 cites W2111047373 @default.
• W2012702392 cites W2113943669 @default.
• W2012702392 cites W2116771437 @default.
• W2012702392 cites W2123946565 @default.
• W2012702392 cites W2124701241 @default.
• W2012702392 cites W2126329856 @default.
• W2012702392 cites W2130400490 @default.
• W2012702392 cites W2130718188 @default.
• W2012702392 cites W2144173715 @default.
• W2012702392 cites W2145344632 @default.
• W2012702392 cites W2149185387 @default.
• W2012702392 cites W2149973065 @default.
• W2012702392 cites W2170276146 @default.
• W2012702392 cites W2170760052 @default.
• W2012702392 cites W2188846692 @default.
• W2012702392 cites W2337454357 @default.
• W2012702392 cites W4248932937 @default.
• W2012702392 doi "https://doi.org/10.1186/2050-6511-14-25" @default.
• W2012702392 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3682882" @default.
• W2012702392 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23631443" @default.
• W2012702392 hasPublicationYear "2013" @default.
• W2012702392 type Work @default.
• W2012702392 sameAs 2012702392 @default.
• W2012702392 citedByCount "29" @default.
• W2012702392 countsByYear W20127023922012 @default.
• W2012702392 countsByYear W20127023922014 @default.
• W2012702392 countsByYear W20127023922015 @default.
• W2012702392 countsByYear W20127023922016 @default.
• W2012702392 countsByYear W20127023922017 @default.
• W2012702392 countsByYear W20127023922018 @default.
• W2012702392 countsByYear W20127023922019 @default.
• W2012702392 countsByYear W20127023922020 @default.
• W2012702392 countsByYear W20127023922021 @default.
• W2012702392 countsByYear W20127023922022 @default.
• W2012702392 countsByYear W20127023922023 @default.
• W2012702392 crossrefType "journal-article" @default.
• W2012702392 hasAuthorship W2012702392A5003799255 @default.
• W2012702392 hasAuthorship W2012702392A5004226439 @default.
• W2012702392 hasAuthorship W2012702392A5015238083 @default.
• W2012702392 hasAuthorship W2012702392A5041396494 @default.
• W2012702392 hasAuthorship W2012702392A5048256222 @default.
• W2012702392 hasAuthorship W2012702392A5050132762 @default.
• W2012702392 hasAuthorship W2012702392A5080178643 @default.
• W2012702392 hasAuthorship W2012702392A5090786280 @default.
• W2012702392 hasBestOaLocation W20127023921 @default.
• W2012702392 hasConcept C111113717 @default.
• W2012702392 hasConcept C112705442 @default.
• W2012702392 hasConcept C126322002 @default.
• W2012702392 hasConcept C134018914 @default.
• W2012702392 hasConcept C149151106 @default.
• W2012702392 hasConcept C22979827 @default.
• W2012702392 hasConcept C2777180221 @default.
• W2012702392 hasConcept C2777477808 @default.
• W2012702392 hasConcept C2780323712 @default.
• W2012702392 hasConcept C2910068830 @default.
• W2012702392 hasConcept C555293320 @default.
• W2012702392 hasConcept C71924100 @default.
• W2012702392 hasConcept C98274493 @default.
• W2012702392 hasConceptScore W2012702392C111113717 @default.
• W2012702392 hasConceptScore W2012702392C112705442 @default.
• W2012702392 hasConceptScore W2012702392C126322002 @default.
• W2012702392 hasConceptScore W2012702392C134018914 @default.
• W2012702392 hasConceptScore W2012702392C149151106 @default.
• W2012702392 hasConceptScore W2012702392C22979827 @default.
• W2012702392 hasConceptScore W2012702392C2777180221 @default.
• W2012702392 hasConceptScore W2012702392C2777477808 @default.
• W2012702392 hasConceptScore W2012702392C2780323712 @default.
• W2012702392 hasConceptScore W2012702392C2910068830 @default.
• W2012702392 hasConceptScore W2012702392C555293320 @default.
• W2012702392 hasConceptScore W2012702392C71924100 @default.
• W2012702392 hasConceptScore W2012702392C98274493 @default.
• W2012702392 hasIssue "1" @default.
• W2012702392 hasLocation W20127023921 @default.

• next